Market Overview

UPDATE: Merck Upgraded by Morgan Stanley on Oncology Optimism

Share:
Related MRK
Barron's Recap: What's Next?
New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN and the TECOS Cardiovascular Safety Trial of JANUVIA Will Be Presented at the European Society of Cardiology Congress
An 80/20 Filter On How The DJIA Weathered The Week (Seeking Alpha)

In a report released Monday, JP Morgan analyst David Risinger upgraded Merck (NYSE: MRK) from Underweight to Overweight with a price target of $60.

Risinger notes, "Mgmt is taking the right steps—cost cuts, R&D changes, and considering strategic action—to boost company's outlook." One of the driving catalysts that the report mentioned is MK-3475, an immuno-oncology candidate which Merck filed for approval a year earlier than expected.

MRK closed Friday at $51.98 and is currently up nearly 3% at the $53.37 level.

Latest Ratings for MRK

DateFirmActionFromTo
Aug 2015JefferiesMaintainsHold
Aug 2015BMO CapitalUpgradesMarket PerformOutperform
Jun 2015Piper JaffrayInitiates Coverage onNeutral

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: News Upgrades Price Target Markets Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters